Review of plasma exchange and rituximab for prevention of recurrent focal segmental glomerulosclerosis after a prior graft loss

Table 3 Individual patient outcomes after treatment for re-recurrence

Patient number	tPE	tPE regime	tRTX	tRTX regime	Treatment outcome
1	+	PE with replacement fluid of one plasma volume of 3.33% albumin solution (0.9% saline and 5% albumin n a 1:2 ratio)	-	-	PR
2	+		-	-	PR
3	+		-	-	NR
12	+	Immunoadsorption 4 times, 10-g of immunoglobulins substituted once	+	375 mg/m2, 3 doses	PR
18	+	1.5 times plasma volume exchange, replaced by a human albumin solution 5%. 3 daily sessions, followed by three-times-a-week for 3 weeks	+	2 doses of 1 g each, 2 weeks apart	CR for 1 year
19	+		+		NR
20	+	Alternate day for 2 weeks, then adapted to proteinuria level. Steroids at 1 mg/kg/day for 3 weeks and then slowly tapered	+	375 mg/m2 of body surface area at the 4th and 8th apheresis sessions	PR
21	+		+		GF
22	+		+		PR
23	+		+		CR
24	+		+		PR

Patient numbers are from Table 1. CR: Complete remission; PR: Partial remission; NR: No remission; GF: Graft failure; tPE: Therapeutic plasma exchange; tRTX: Therapeutic rituximab.